Medtronic's 0.36% Gain with $520M Volume Places Stock 188th in Trading Volume Amid Strategic Expansion and Supply Chain Pressures

On September 23, 2025, , , . , indicating moderate investor engagement. Recent developments highlight Medtronic’s strategic focus on expanding its minimally invasive surgical portfolio through product launches and partnerships in emerging markets. , though near-term execution risks remain. The company’s recent earnings report emphasized cost optimization initiatives, . Market participants remain cautious as the firm navigates supply chain challenges in its key endoscopy and cardiac rhythm businesses.

To execute this back-test, . . . , 2022, . Proposals to narrow the universe (e.g., . .